Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2023-03-31 Capital/Financing Update
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
S-8
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans and employee stock purchase plans. It includes details about the number of shares to be registered, references to prior registration statements, and exhibits related to corporate governance documents and legal opinions. There are no financial statements or earnings data, nor is this an announcement of a report or a certification. This type of filing is related to capital raising through employee stock plans and thus fits the category of Capital/Financing Update (CAP).
2023-03-31 English
10-K
Annual Report FY 2022
2023-03-31 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-20 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content specifically discloses that the company does not hold cash deposits or securities at Silicon Valley Bank, which is a Regulation FD Disclosure. There are no financial statements or detailed financial data present, and the document is relatively short (4870 characters). This is a typical regulatory announcement rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-03-10 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-07 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-02 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.